Right to Try Act of 2017
- Last Action
- 3/2/2017
Actions
- 2017-03-02Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
- 2017-03-02Referred to the Subcommittee on the Constitution and Civil Justice.
- 2017-02-10Referred to the Subcommittee on Health.
- 2017-02-06Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2017-02-06Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2017-02-06Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2017-02-06Introduced in House
- 2017-02-06Introduced in House
CRS Summary
As of 2017-02-06 (00)
Right to Try Act of 2017
This bill requires the federal government to allow unrestricted manufacturing, distribution, prescribing, and dispensing of experimental drugs, biological products, and medical devices that are: (1) intended to treat a patient who has been diagnosed with a terminal illness, and (2) authorized by state law. The federal government must allow unrestricted possession and use of such treatments by patients certified by a physician as having exhausted all other treatment options.
A manufacturer, distributor, prescriber, dispenser, possessor, or user of such a treatment has no liability regarding the treatment.
The outcome of manufacture, distribution, prescribing, dispensing, possession, or use of such a treatment may not be used by a federal agency to adversely impact review or approval of the treatment.
The treatment must: (1) have successfully completed a phase 1 (initial, small scale) clinical trial; (2) remain under investigation in a clinical trial approved by the Food and Drug Administration; and (3) not be approved, licensed, or cleared for sale under the Federal Food, Drug, or Cosmetic Act or the Public Health Service Act.
Cosponsors (20)
- Brian Fitzpatrick (R-PA)
- Kevin Cramer (R-ND)
- Glenn Grothman (R-WI)
- Luke Messer (R-IN)
- Robert Pittenger (R-NC)
- Chris Stewart (R-UT)
- Leonard Lance (R-NJ)
- Pete Olson (R-TX)
- Trent Franks (R-AZ)
- Doug Lamborn (R-CO)
- André Carson (D-IN)
- Martha McSally (R-AZ)
- Ted Yoho (R-FL)
- DANA ROHRABACHER (R-CA)
- Jeff Duncan (R-SC)
- Jason Lewis (R-MN)
- Andy Barr (R-KY)
- Jim Bridenstine (R-OK)
- Louie Gohmert (R-TX)
- Jim Banks (R-IN)
Subjects
- Civil actions and liability
- Drug safety, medical device, and laboratory regulation
- Drug therapy
- Health technology, devices, supplies
- Licensing and registrations
- Long-term, rehabilitative, and terminal care
- Prescription drugs
- Product safety and quality
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.